US 9,308,280 B2 · Targeting of antigen presenting cells with immunonanotherapeutics

Targeting of antigen presenting cells with immunonanotherapeutics

AssigneesMassachusetts Institute of Technology, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.

InventorsJinjun Shi, Frank Alexis, Matteo Iannacone, Elliott Ashley Moseman, Pamela Basto, Robert S. Langer, Omid C. Farokhzad, Ulrich H. von Andrian, Elena Tonti

Life of this patent

Estimating the term…

Abstract

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.

Claims23

Dependent claims

A composition comprising:

(a) polymeric particles formed from the self-assembly of a mixture of amphiphilic (hydrophobic-hydrophilic) polymers and amphiphilic polymers having at least one moiety bound to the hydrophilic ends of the amphiphilic polymers;
(b) a B cell or T cell antigen;
(c) an immunostimulatory agent to promote tolerance to the antigen;
and
(d) a pharmaceutically acceptable excipient.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/046,827Filed 4 Oct 2013 · continuation

Priority

12 Oct 2008

Published

US 2014/0037736 A16 Feb 2014

Granted

12 Apr 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 47/6925
The form being a particulate, a powder, an adsorbate, a bead or a sphere: the form being a microcapsule, nanocapsule, microbubble or nanobubble
A61K 39/00
Medicinal preparations containing antigens or antibodies
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/13
Characterised by the cell type used: b-cells

Family

PCT/US2008/011932Parent of this continuation-in-part · filed 12 Oct 2008

Application12/428,381Parent of this continuation · filed 22 Apr 2009

PCT/US2009/060250Parent of this continuation · filed 9 Oct 2009

US 8,343,497 B2Parent of this continuation · filed 1 Jan 2013

US 2014/0037736 A1Pre-grant publication · published 6 Feb 2014

Application13/123,884Parent of this continuation

US 8,562,998 B2Parent of this continuation

Application12/428,381Parent of this continuation-in-part

US 2010/0129392 A1Published application

US 2011/0268804 A1Published application

US 9,308,280 B2This patent

From the US filing history. Foreign family members aren’t listed.